These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29649539)

  • 1. Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
    Bonadonna RC; Renard E; Cheng A; Fritsche A; Cali A; Melas-Melt L; Umpierrez GE
    Diabetes Res Clin Pract; 2018 Aug; 142():19-25. PubMed ID: 29649539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
    Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
    Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3.
    Yale JF; Pettus JH; Brito-Sanfiel M; Lavalle-Gonzalez F; Merino-Trigo A; Stella P; Chevalier S; Buzzetti R
    PLoS One; 2018; 13(1):e0190579. PubMed ID: 29370218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
    Riddle MC; Yki-Järvinen H; Bolli GB; Ziemen M; Muehlen-Bartmer I; Cissokho S; Home PD
    Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Terauchi Y; Riddle MC; Hirose T; Koyama M; Cheng X; Takahashi Y; Bolli GB
    Diabetes Obes Metab; 2018 Nov; 20(11):2541-2550. PubMed ID: 29888454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.
    Ritzel R; Roussel R; Bolli GB; Vinet L; Brulle-Wohlhueter C; Glezer S; Yki-Järvinen H
    Diabetes Obes Metab; 2015 Sep; 17(9):859-67. PubMed ID: 25929311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).
    Matsuhisa M; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
    Diabetes Res Clin Pract; 2016 Dec; 122():133-140. PubMed ID: 27835765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].
    Bohn B; Bramlage P; Wagner C; Kaltheuner M; Welp R; Sziegoleit S; Zimmermann A; Reuter HM; Hummel M; Gloyer J; Holl RW; Danne T
    Wien Med Wochenschr; 2018 Nov; 168(15-16):415-422. PubMed ID: 28828553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.
    Bolli GB; Wysham C; Fisher M; Chevalier S; Cali AMG; Leroy B; Riddle MC
    Diabetes Obes Metab; 2019 Feb; 21(2):402-407. PubMed ID: 30160030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
    Goldman J; White JR
    Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.
    Riddle MC; Bolli GB; Avogaro A; Gimenez Álvarez M; Merino-Trigo A; Boëlle-Le Corfec E; Home PD
    Diabetes Metab; 2018 Sep; 44(4):333-340. PubMed ID: 29277378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials.
    Danne T; Matsuhisa M; Sussebach C; Goyeau H; Lauand F; Niemoeller E; Bolli GB
    Diabetes Obes Metab; 2020 Oct; 22(10):1880-1885. PubMed ID: 32515543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus.
    Brown MA; Davis CS; Fleming LW; Fleming JW
    J Am Assoc Nurse Pract; 2016 Sep; 28(9):503-9. PubMed ID: 26990724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
    Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
    Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
    Sullivan SD; Freemantle N; Gupta RA; Wu J; Nicholls CJ; Westerbacka J; Bailey TS
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.